Harrisson S et al. Six month interim results of MSDC-0602K in a large phase 2b NASH study demonstrate significant improvement in liver enzymes and glycemic control (NCT02784444). (Abstract PS-111)
PREVAIL IV: vaker ebolavirus-RNA-negatief na behandeling remdesivir
jul 2021 | Virale infecties